Single arms prospective phase II study of SBRT for oligometastatases from colorectal cancer
Single arms prospective phase II study of SBRT for oligometastatases from colorectal cancer, the primary concerns are treatment efficacy and toxicities.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
50
All patients will undergo planning CT simulation. 4-dimensional CT will be used for tumors in the lungs or liver. For all lesions, the gross tumor volume (GTV) will be defined as the visible tumor on CT and/or MRI imaging +/- PET. A Planning Target Volume (PTV) margin of 3-5 mm will be added depending on site of disease, immobilization, and institutional set-up accuracy. The prescirbe dosage was as following: Lung lesion DT50-60 Gy/5 fractions; liver 50-60Gy/5-8 fractions; brain DT 40Gy/4-5fractions. All will be treated with SBRT
Cancer Hospital Chinese Acadamy of Medical Sciences
Beijing, Beijing Municipality, China
RECRUITINGlocal control assessed by RECIST
Time frame: 3 years
>= Grade 3 treatment-related adverse events as assessed by CTCAE v4.0
Time frame: from radiotherapy start to complete treatment 90 days
overall survival
Time frame: 3 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.